Predict your next investment

HEALTHCARE | Biotechnology
u-proteinexpress.com

See what CB Insights has to offer

Stage

Acquired | Acquired

About U-Protein Express

U-Protein Express provides mammalian recombinant proteins and antibodies for clients' research and pre-clinical applications, and holds the rights to proprietary expression technology used in antibody production.

U-Protein Express Headquarter Location

Utrecht Science Park Yalelaan 62

Utrecht, 3584,

Netherlands

+31 (0) 30 253 7903

Latest U-Protein Express News

Recombinant SARS-CoV-2 Proteins Now Available for Research from U-Protein Express

Jun 16, 2020

Published on June 16, 2020 New recombinant SARS-CoV-2 proteins, along other proteins associated with covid-19, from U-Protein Express (UPE), Utrecht, Netherlands, are now available for use by researchers globally for the design and discovery of novel therapeutics, vaccines, and diagnostic test kits for coronavirus. UPE is a subsidiary of ImmunoPrecise Antibodies, Victoria, British Columbia, Canada. “UPE’s management stepped up immediately in early January, soon after the emergence of SARS-CoV-2, and began the construct design and manufacturing of proteins that play a central role in the infection of human lung tissue by the SARS-CoV-2 virus,” says Roland Romijn, PhD, head of general pperations at UPE. “By using ImmunoPrecise’s proprietary rPExTM protein production platform, we have produced high-quality, high-yield batches of multiple subunits of the viral spike protein, and other SARS-CoV-2-related proteins, which we believe are useful reagents for the analysis of, and generation of, antibody therapeutics, vaccines, and diagnostics. We continue to focus on the development of new, SARS-CoV-2-related recombinant proteins to support the scientific community in this crucial, global effort.” These proteins are now available to the scientific community to help combat the current covid-19 pandemic crisis. The recombinant coronavirus proteins (and other proteins related to SARS-CoV-2 infection) are produced using ImmunoPrecise’s proprietary rPEx protein production platform, utilizing transient transfection of HEK293 cells. In contrast to more basic recombinant protein expression platforms like E. coli cells or insect cells, the rPEx platform generates superior recombinant proteins that more closely resemble the native conformations of the proteins. This is especially important for retaining the functions of the heavily glycosylated, viral spike protein. “The success of this program at UPE is an exemplary demonstration of the selfless efforts, unity, and determination that have arisen within ImmunoPrecise as part of our larger, global efforts in fighting coronavirus,” says Jennifer Bath, PhD, president and chief executive officer of ImmunoPrecise. “The substantive time and energy dedicated by this team have not only enabled this much needed support to the broader scientific community but have also served as a cornerstone in our own efforts at IPA, as we continue to rapidly advance our coronavirus therapeutic, vaccine and diagnostic programs.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

U-Protein Express Patents

U-Protein Express has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/14/2009

12/25/2012

Molecular biology, Proteins, Protein domains, Opioid peptides, Bioinformatics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/14/2009

00/00/0000

Grant Date

12/25/2012

00/00/0000

Title

Subscribe to see more

Related Topics

Molecular biology, Proteins, Protein domains, Opioid peptides, Bioinformatics

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.